Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
A-005 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose (SAD) | EXPERIMENTAL | - |
| Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | - |
| Part C: Lumbar Puncture | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| A-005 | DRUG | Single oral dose of A-005 |
| Placebo | DRUG | A-005 matched placebo |
Inclusion Criteria: * Healthy, adult, male or female 19-55 years of age, inclusive, at the screening visit. * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit. * Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles,...
A-005 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and tolerability. The drug is not approved for any indication and remains under investigation.
A-005 is being developed by Alumis Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALMS. The company is conducting clinical research on this investigational small molecule.
A-005 is in Phase 1 clinical development. A Phase 1 trial has been completed, which studied the safety and tolerability of single and multiple ascending doses of the drug in healthy volunteers. It remains an investigational drug and is not yet approved.
A-005 has one completed Phase 1 clinical trial, identified as NCT07442149. This study evaluated the safety and tolerability of single and multiple ascending doses of A-005 in 135 healthy volunteers in the United States. The trial was randomized, double-blind, and controlled.
A-005 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial in healthy volunteers has been completed, but the drug has not yet received regulatory approval for any use.